International expert consensus on immunotherapy for early-stage non-small cell lung cancer.

Transl Lung Cancer Res · 2022 · PMC9554679 · PMID 36248334

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

For patients with high PD-L1 expression, pembrolizumab showed a favorable trend, but the pre-specified statistical difference was not reached.

also in 1,335 other papers

showed a trendno p-value reported

Subgroup analysis revealed that patients with EGFR mutations (n=73) showed a trend favoring pembrolizumab (HR: 0.44; 95% CI: 0.23–0.84), which was more prominent than that in patients without EGFR mutations (n=434) (HR: 0.78; 95% CI: 0.59–1.05) ( 29 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.